Categorynews

Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings

May 2, 2019 Off By BusinessWire

– Recent analyses highlight significant unmet clinical needs and
burden of anemia due to chronic kidney disease

CAMBRIDGE, Mass. & PRINCETON, N.J.–(BUSINESS WIRE)–Akebia
Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company
focused on the development and commercialization of therapeutics for
patients with kidney disease, and its strategic development collaborator
Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC),
announced today that four posters highlighting the unmet clinical need
and economic burden among patients with anemia due to chronic kidney
disease will be presented at the 2019 Spring Clinical Meetings of the
National Kidney Foundation (NKF), to be held May 8 through May 12, 2019
at the Hynes Convention Center in Boston, MA.

A Review of Cost-effectiveness Analyses for Anemia in Chronic Kidney
Disease; Poster #188;
Descriptions of Anemia Symptoms: A Linguistic Analysis of Social Media
Conversations in Chronic Kidney Disease; Poster #190;
Targeted Review of the Epidemiology and Burden of Anemia in Chronic
Kidney Disease; Poster #191; and
Targeted Literature Review of the Patient-reported Burden of Anemia in
Chronic Kidney Disease; Poster #192.

“Akebia and Otsuka are committed to innovation and quality clinical
research to advance the standard of care for patients with kidney
disease,” said John P. Butler, President and Chief Executive Officer of
Akebia Therapeutics. “Together we are delighted that these analyses will
be shared at this important clinical meeting to increase awareness and
understanding of the economic burden and challenges faced by patients
with anemia due to chronic kidney disease.”

Presenters will be available for questions at posters on Thursday, May
9, 2019, from 6:00-7:30 p.m. ET. Posters will be available for viewing
over the course of the conference.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical
company focused on the development and commercialization of therapeutics
for patients with kidney disease. The company was founded in 2007 and is
headquartered in Cambridge, Massachusetts. For more information, please
visit Akebia’s website at www.akebia.com,
which does not form a part of this release.

About Otsuka
Otsuka Pharmaceutical Company is a global
healthcare company with the corporate philosophy: “Otsuka–people
creating new products for better health worldwide.” Otsuka researches,
develops, manufactures and markets innovative products, with a focus on
pharmaceutical products to meet unmet medical needs and nutraceutical
products for the maintenance of everyday health.

In pharmaceuticals, Otsuka is a leader in the challenging areas of
mental, renal and cardiovascular health and has additional research
programs in oncology and on several under-addressed diseases including
tuberculosis, a significant global public health issue. These
commitments illustrate how Otsuka is a “big venture” company at heart,
applying a youthful spirit of creativity in everything it does.

Otsuka established a presence in the U.S. in 1973 and today its U.S.
affiliates include Otsuka Pharmaceutical Development &
Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc.
(OAPI). These two companies’ 1,700 employees in the U.S. develop and
commercialize medicines in the areas of mental health, nephrology and
cardiology, using cutting-edge technology to address unmet healthcare
needs.

OPDC is an indirect subsidiary of Otsuka Pharmaceutical Company, Ltd.,
which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in
Tokyo, Japan. The Otsuka group of companies employed 47,000 people
worldwide and had consolidated sales of approximately USD 11.7 billion
in 2018.

All Otsuka stories start by taking the road less travelled. Learn more
about Otsuka in the U.S. at www.otsuka-us.com
and connect with us on LinkedIn
and Twitter at @OtsukaUS.
Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at www.otsuka.co.jp/en/.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of
the federal securities laws. Such statements are based upon current
plans, estimates and expectations that are subject to various risks and
uncertainties. The inclusion of forward-looking statements should not be
regarded as a representation that such plans, estimates and expectations
will be achieved. Words such as “anticipate,” “create,” “expect,”
“project,” “intend,” “believe,” “may,” “will,” “should,” “plan,”
“could,” “target,” “contemplate,” “estimate,” “position,” “predict,”
“potential,” “opportunity,” “working to,” “look forward” and words and
terms of similar substance used in connection with any discussion of
future plans, actions or events identify forward-looking statements. All
statements, other than historical facts, including statements regarding
advancing the standard of care for patients with kidney disease, and
increasing awareness and understanding of the economic burden and
challenges faced by patients with anemia due to chronic kidney disease,
are forward-looking statements. Important factors could cause actual
results to differ materially from Akebia’s plans, estimates or
expectations. Other risks and uncertainties include those identified
under the heading “Risk Factors” in Akebia’s Annual Report on Form 10-K,
and other filings that Akebia may make with the U.S. Securities and
Exchange Commission in the future. Akebia does not undertake, and
specifically disclaims, any obligation to update any forward-looking
statements contained in this press release.